Literature DB >> 11284983

Primary malignant melanoma of the esophagus.

H A Archer1, W J Owen.   

Abstract

is a rare disease, with only 200 cases being reported since this condition became an established clinical entity in 1963. This tumor, which accounts for only 0.1-0.2% of all esophageal neoplasms, is typically aggressive and disseminates early via the bloodstream and lymphatics, with only some 30% of patients surviving > 1 year after diagnosis. Management of patients with esophageal melanomata is unsatisfactory, as most tumors are advanced at diagnosis, and therapeutic options are limited by inaccessibility and early dissemination of the neoplasms. Poor survival rates reflect the inoperability of many tumors and the ineffectiveness of radiation and chemotherapy in eradicating advanced tumors and metastases. We present two patients with primary melanoma of the esophagus and discuss the treatment options currently available.

Entities:  

Mesh:

Year:  2000        PMID: 11284983     DOI: 10.1046/j.1442-2050.2000.00140.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  10 in total

1.  Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy.

Authors:  R Díaz; P Moral; M Fonfría; M de Juan; N Mancheño; A Tormo
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

2.  Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.

Authors:  Yoshihiro Suzuki; Norio Aoyama; Junji Minamide; Ken Takata; Takashi Ogata
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

3.  Concurrence of primary malignant melanoma of the esophagus with adenocarcinoma of sigmoid colon and villous adenoma of cecum: a case presentation.

Authors:  Kursat Dikmen; Zafer Ferahkose; Barıs Turhan; Gizem Toker Caliskan; Hasan Bostanci; Cagri Buyukkasap; Selim Keceoglu; Bulent Aytac
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Synchronous primary oesophageal malignant melanoma and sigmoid adenocarcinoma.

Authors:  Ahsan Malik; Sandeep Bansil; Naushad Junglee; Jonathon Sutton; Jaber Gasem; Waqar Ahmed
Journal:  BMJ Case Rep       Date:  2011-07-28

5.  Acute esophageal necrosis and low-flow state.

Authors:  Ahmad Burtally; Philippe Gregoire
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

6.  Clinicopathological Features, Staging Classification, and Clinical Outcomes of Esophageal Melanoma: Evaluation of a Pooled Case Series.

Authors:  Haiyan Sun; Ningning Zhu; Lei Gong; Lan Lan; Zhentao Yu; Zhanyu Pan
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

7.  Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients.

Authors:  Xuan Wang; Yan Kong; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Lili Mao; Bin Lian; Bixia Tang; Xieqiao Yan; Lu Si; Jun Guo
Journal:  Thorac Cancer       Date:  2019-03-12       Impact factor: 3.500

8.  Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report.

Authors:  Shingo Ito; Yuji Tachimori; Yuichi Terado; Ryota Sakon; Kazuhiro Narita; Manabu Goto
Journal:  J Med Case Rep       Date:  2021-05-05

Review 9.  The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus.

Authors:  Gerardo Cazzato; Eliano Cascardi; Anna Colagrande; Teresa Lettini; Leonardo Resta; Cinzia Bizzoca; Francesca Arezzo; Vera Loizzi; Miriam Dellino; Gennaro Cormio; Nadia Casatta; Carmelo Lupo; Antonio Scillimati; Salvatore Scacco; Paola Parente; Lucia Lospalluti; Giuseppe Ingravallo
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

10.  Primary malignant melanoma of the esophagus arising from a melanotic lesion: report of a case.

Authors:  Takashi Oshiro; Hideaki Shimoji; Fumiaki Matsuura; Nobufumi Uchima; Fukunori Kinjo; Takashi Nakayama; Tadashi Nishimaki
Journal:  Surg Today       Date:  2007-07-26       Impact factor: 2.540

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.